

1 **TITLE PAGE**

2 **Title of the article** Weight loss in patients with COVID-19 and Influenza in comorbidity with
3 NCDs: a pilot prospective clinical trial.

4 **Running head:** Weight loss for COVID-19/Influenza: a pilot prospective clinical trial

5 **AUTHORS**

6 Kuat Oshakbayev (corresponding author)^{1, 10}, MD, PhD, DMSc, professor; Aigul Durmanova²
7 , MD, PhD, DMSc; Alisher Idrisov³, MD, PhD, DMSc; Zulfiya Zhankalova⁴, MD, PhD, DMSc;
8 Gulnara Bedelbayeva⁵ MD, PhD, DMSc, associate professor; Meruyert Gazaliyeva⁶, MD,
9 PhD, DMSc, professor; Attila Tordai⁷, PhD, DSc, professor; Altay Nabiyev⁸, MD, PhD;
10 Bibazhar Dukenbayeva^{9, 10}, MD, PhD, associate professor.

11 **Affiliations of authors:**

12 ¹ University medical center, Internal Medicine Department. Street Syganak, 46, 010000,
13 Astana, Kazakhstan. Mob. phone: +7-701-3999394; e-mail: okp.kuat@gmail.com;
14 kuat.oshakbayev@umc.org.kz

15 ² University medical center, Internal Medicine Department. Street Syganak, 46, 010000,
16 Astana, Kazakhstan. Mob. phone: +7-7772637736; E-mail: aiguldurmanova@mail.ru

17 ³ Medical University Astana, Department of Endocrinology, Astana, Kazakhstan. Tel.mob.:
18 +7-7015140583; E-mail: aliser73@mail.ru

19 ⁴ Asfendiyarov Kazakh National Medical University, Department of General Medical Practice
20 #1. Street Tole Bi, 94. Almaty 050000, Kazakhstan). Tel.mob.: +77026043940; E-mail:
21 z.zhankalova@kaznmu.kz ; zulfiya-zhankalo@mail.ru

22 ⁵ Asfendiyarov Kazakh National Medical University, Faculty of postgraduate education. Street
23 Tole Bi, 94. Almaty 050000, Kazakhstan). Tel.mob.: +77772281581; E-mail:
24 bedelbaeva@mail.ru

25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 ⁶ Medical University Karaganda, Faculty of Internal Medicine. Street Gogol, 40, Karaganda,
27 Kazakhstan. Tel.mob.: +7-7075555514; e-mail: Gazaliev@qmu.kz ;

28 gazaliyeva@yandex.ru

29 ⁷ Semmelweis University, Dept. Transfusion Medicine. H-1088 Budapest, Vas u. 17,
30 Hungary; email: tordai.attila@med.semmelweis-univ.hu

31 ⁸ University medical center, Internal Medicine Department. Street Syganak, 46, 010000,
32 Astana, Kazakhstan. Mob. phone: +7 701 908 2725; e-mail: a.nabiyev@umc.org.kz

33 ⁹ Medical University Astana, Faculty of pathology and forensic medicine, Astana, Kazakhstan.
34 Tel.mob.: +7-7013999141; E-mail: dukenbaeva74@gmail.com

35 ¹⁰ ANADETO medical center, st. Kerey, Zhanibek khans, 22, Astana, 010000, Kazakhstan.

36 **Corresponding Author:** Kuat Oshakbayev. University medical center, Internal Medicine
37 Department. The Republic of Kazakhstan, 010000, Astana, str. Syganak, 2. Mob. phone: +7-
38 7013999394. Email: okp.kuat@gmail.com; kuat.oshakbayev@umc.org.kz

39 **Funding:** This research was supported by Ministry of Education and Science of the Republic
40 of Kazakhstan (Grant for 2018-2021 years with trial registration AP05135241, National
41 Center for Scientific and Technical Information of the Republic of Kazakhstan. K.O., a PI of
42 the project, is supported by the Ministry of health of the Republic of Kazakhstan, 2020-2021.

43 **Word count (excluding abstract and references):** 4150

44 **Number of Tables:** 2

45 **Number of Figures:** 1

46 **Number of Photos:** 0

47 **Number of References:** 73.

48 **ABSTRACT**

49 **Background** COVID and Influenza with non-communicable chronic diseases (NCDs)
50 complicate the diagnosis, treatment, prognosis, and increase mortality rate. The aim: to

51 evaluate the effects of the fast weight loss on clinic and laboratory inflammation profile,
52 metabolic profile, reactive oxygen species (ROS) and body composition in patients with COVID
53 and Influenza in comorbidity with NCDs.

54 **Methods:** A 6-week open, pilot prospective clinical trial including 62 adult patients with COVID
55 (n=27) and influenza (n=35) in comorbidity with T2D, hypertension, and NASH. Overweight in
56 33 patients (53.2%) with BMI 28.14 ± 0.39 kg/m², and 29 patients without overweight with BMI
57 23.37 ± 0.38 kg/m². T2D in 26 (41.9%); Hypertension in 38 (61.3%) (incl. 12 patients with T2D);
58 NASH in 51 patients (82.2%) (incl. 8 patients with NASH, T2D and Hypertension; 6 patients
59 with NASH and T2D; 18 patients with NASH and Hypertension; 19 patients with only NASH).
60 Primary endpoints: Clinic/infectious/inflammation tests for COVID and Influenza; weight loss
61 during 14 days. Secondary endpoints: fasting blood glucose, HbA1c, blood insulin;
62 systolic/diastolic BP; blood lipids; ALT, AST, chest CT-scan.

63 **Results:** The patients with overweight lost -12,4% from baseline or BMI= -4.2 kg/m², and
64 patients without overweight lost -9,14% from baseline or BMI= -2.2 kg/m² (-9.7±0.7 kg vs. -
65 6.4±0.6 kg, respectively; $P < 0.001$) at 14-day of the treatment. Weight loss in both groups was
66 due to reduction of fat mass ($P < 0.0001$).

67 Sputum production increased in 1.0-1.5 liter/day on 2-3 days, decreased in 7-9 days. Body
68 temperature normalized in 6-9 days. On 3-5 days, in most patients their urine became
69 turbid/muddy/intensively colored. Urine microscopy showed organic and non-organic salts, and
70 leukocyturia (20-35/sight).

71 White blood cells, lymphocytes, NLR normalized at 14 days ($P < 0.0001$). Total-fibrinogen, C-
72 reactive-protein, and Erythrocyte-sedimentation-rate, ROS normalized at 14-day of treatment
73 ($P < 0.0001$).

74 COVID and Influenza were a negative in >96.3% patients at 14-day. Systolic/diastolic BP
75 decreased ($161.3 \pm 1.31 / 101.6 \pm 0.85$ vs. $118.3 \pm 0.46 / 80.89 \pm 0.66$, $P < 0.0001$), glucose and lipids
76 metabolism in patients with T2D (n=26) ($P < 0.0001$); ALT and AST in patients with NASH

77 (n=51) were significantly normalized (from baseline 134.3 ± 5.4 and 166.5 ± 5.5 U/L, respectively,
78 and at 14-day to 78.4 ± 4.2 and 92.4 ± 4.9 U/L, respectively ($P<0.0001$)), platelets increased from
79 baseline (186.5 ± 4.6 , $\times 10^9/L$) at 14-day of treatment (238.5 ± 5.8 , $\times 10^9/L$) ($P<0.0001$), and at 6-
80 week follow-up (278.3 ± 6.9 , $\times 10^9/L$) ($P<0.0001$). The mean score of chest-CT for the patients
81 (n=44) was 13.12 ± 0.38 from baseline, and at 14-day the score was 1.72 ± 0.12 ($P<0.0001$).
82 ROS level normalized at 14-day treatment and 6-week follow-up from baseline ($P<0.0001$).
83 The previous antidiabetic, antihypertensive, anti-inflammatory and hepatoprotective, and other
84 symptomatic medications were adequately decreased in 2-5 days to completely stopping by 5-
85 8 days treatment.

86 **Conclusions:** The fast weight loss is clinical/laboratory benefit in treatment of patients with
87 COVID-19 and Influenza in comorbidity with T2D, hypertension, and NASH.

88 **Trial Registration:** ClinicalTrials.gov NCT05635539. Registered 1 December 2022.

89 **Keywords:** COVID, Influenza, type 2 diabetes mellitus; hypertension, NASH, fast weight loss;
90 inflammation/glycemic/lipid profile; chest CT; lipid/protein oxidation.

91 **1. INTRODUCTION**

92 SARS-CoV-2, a virus which causes the disease known as COVID-19 (further – COVID), was
93 first described in a case of pneumonia of unknown origin in Wuhan City, China but quickly
94 evolved into a worldwide pandemic, and has changed the mortality rate. (1-3) COVID and
95 Influenza are the most common acute respiratory diseases (ARD) in the world, which can
96 quickly spread through the air and direct contact. (2, 4, 5) The ARDs are serious illnesses that
97 >100 millions of people in the worldwide get each year. It sends millions of people to the
98 hospital and causes millions of deaths. (6, 7) The increased ranking of COVID as a leading
99 cause of death in some age groups is consistent with a downward age shift in the distribution
100 of COVID deaths in last years. (3, 8)

101 COVID and Influenza co-infection with other non-communicable chronic diseases (NCDs)
102 complicate the diagnosis, treatment, prognosis of the ARDs emerge new concern. (9, 10) This
103 comorbidity may even increase the disease symptom and mortality rate. Aggravating affects
104 of the ARDs on cardiovascular comorbidities, diabetes onset, and chronic liver and kidney
105 diseases have long been debating. (11, 12) Older age and type 2 diabetes (T2D), hypertension,
106 liver and kidney diseases were significantly associated with an increased likelihood of
107 mortality. (13) NCDs are also leading cause of mortality and morbidity in the world. (14, 15)

108 Pharmacology treatment of ARDs and NCDs evidenced positive results, but it is still
109 insufficiently, due to many problems related with their effectiveness, wide side-effects,
110 sensitivity and specificity, etc. (14, 16, 17) Vaccination for controlling COVID and Influenza
111 infectious diseases continues to be the most effective method. Nonetheless, COVID and
112 Influenza variants continue to evolve and emerge, resulting in significant public concerns
113 worldwide. (3, 18)

114 Pharmacologic and bio-vaccine treatment are not always can help to cure the ARDs due to
115 they have a lot of side effects during and post treatment period. Treatment of the ARDs is more
116 difficult in patients with comorbidities as T2D, hypertension, and nonalcoholic steatohepatitis

117 (NASH). (19-21) Therefore, searching reliable, secure, and natural methods for treatment of
118 COVID and Influenza are continuing in the worldwide. (3, 5, 17, 18, 22)
119 NCDs and COVID are spreading in countries with a higher rate of overweight. (10, 23-27) The
120 Comprehensive Assessment of the Long-term Effects of Reducing Intake of Energy (CALERIE)
121 phase 2 trial showed that moderate reduction of energy intake averaging approximately 12%
122 over 2 years could improve markers of inflammation, cardiometabolic health, and oxidative
123 stress in humans. (28, 29) Caloric restriction has been shown to extend life span and health
124 span in many animal species.(30) There has been growing interest in evaluating related
125 strategies, such as intermittent fasting, periodic fasting, and time-restricted eating that may
126 achieve the putative benefits of caloric restriction with greater likelihood of sustainability. (31)
127 COVID affects different people in different ways. Most infected people will develop mild to
128 moderate illness and recover without hospitalization. Some studies reported a high prevalence
129 of overweight and obesity in patients experiencing a severe COVID course, with serious
130 complications requiring hospitalization and admission to intensive care units. (27) Patients with
131 obesity require regularly taking medications for the treatment of any concurrent
132 chronic diseases, their physicians must promptly manage any medical symptoms in the case
133 of suspected acute respiratory syndrome infection to prevent the risk of severe outcomes. (32)
134 ARDs with overweight are associated with an increase in oxidative stress and a decrease in
135 antioxidant protection. (23) Acute inflammation in patients with overweight extreme difficulties
136 in treatment and highlight the need for preventive measures. (33)
137 Pharmacological treatment of ARDs with NASH is a great challenge for medicine, because the
138 patients are often limited to take medicine due to persistent progression, increasing of
139 hepatocellular injury/ inflammation, and medicinal overloading. (20)
140 In previous studies we showed a significant impact of overweight/obesity prevalence on the
141 increase in COVID morbidity/mortality, (26) and beneficial role of our weight loss method in
142 improving glycemic, lipid and hormone profiles, electrolyte and biochemical indices, blood

143 pressure, reactive oxygen species and bone mineral density in patients with T2D,
144 hypertension, and severe NASH. (34, 35) The aim of the study was: to evaluate the effects of
145 our fast weight loss method on clinic and laboratory inflammation profile, metabolic profile,
146 reactive oxygen species (ROS) level and body composition in patients with COVID and
147 Influenza in comorbidity with T2D, hypertension, and NASH.

148 **2 STUDY DESIGN AND PARTICIPANTS**

149 *Study Design.* A 6-week, open, pilot prospective clinical trial with the intention-to-treat principle.

150 **2.1 Participants** The study enrolled 72 adult people (38 women) aged from 25 to 80 years with
151 moderate-to-severe cases COVID and Influenza in comorbidity with NCDs as T2D,
152 hypertension, and NASH; 6 patients were excluded due to noncompliance of inclusion and
153 exclusion criteria. Of the remaining 66 patients 4 patients (6.5%) dropped out prior to the study
154 completion: 2 patients refused the treatment method in 3 days after starting, and 1 patient
155 moved to another city, 1 patient was excluded due to noncompliance. (**Fig. 1**) A control
156 pharmacology group was not used because medicinal treatment was unacceptable due to
157 NASH in most of the patients. Thus, 62 patients (36 women) included for the analysis; 27
158 patients with COVID and 35 patients with Influenza. Overweight in 33 patients (53.2%) with
159 body mass index (BMI) 28.14 ± 0.39 kg/m², and 29 patients without overweight with BMI 23.37
160 ± 0.38 kg/m². T2D in 26 (41.9%); Hypertension in 38 (61.3%) (incl. 12 patients with T2D); NASH
161 in 51 patients (82.2%) (incl. 8 patients with NASH, T2D and Hypertension; 6 patients with
162 NASH and T2D; 18 patients with NASH and Hypertension; 19 patients with only NASH). Thus,
163 all patients with the ARDs had in comorbidity with one or more NCDs. All patients with T2D
164 were on Metformin, Sulfonylurea, DPP-4 inhibitors, GLP-1 receptor agonists, Glitazones in
165 different combinations. All patients with hypertension received antihypertensive treatment.
166 All patients refused for pharmacology therapy due to: either previous unsuccessful drug
167 results; or an antimicrobial resistance profile; or drug allergy; or reluctance to take medication;
168 or iatrogenic fear (iatrophobia); or a rich failed experience in drug treatment; and NASH.

169 All the patients were admitted into the out-patient department in 3-5 days after illness onset.
170 The participants were recruited gradually as they come in the Republican Diagnostic Center at
171 University Medical Center (Astana) and ANADETO medical center from November 2020 to
172 March 2022. The study was carried out in the Republic of Kazakhstan from November, 2020,
173 through July, 2022.

174 **Inclusion criteria:** 1) written informed consent form; 2) patients with fever; 3) patients refused
175 for pharmacology therapy; 4) weight loss treatment for 12-14 days and +4 weeks follow-up
176 (total 6 weeks).

177 **Exclusion criteria:** 1) patients with acute respiratory failure and assisted ventilation
178 requirement; 2) respiratory rate ≥ 30 times per minute; 3) oxygen saturation $\leq 93\%$ by finger
179 oximetry at resting status.

180 **Outcome measures Primary endpoints:** Clinic and infectious tests for COVID and Influenza;
181 weight loss during 14 days; inflammation profile. **Secondary endpoints:** fasting blood glucose,
182 glycosylated hemoglobin A1c (HbA1c), blood insulin; systolic/diastolic blood pressures (BP);
183 blood lipids; alanine aminotransferase (ALT), aspartate aminotransferase (AST), chest
184 computed tomography (CT) scan.

185 **2.2 Analytical Assessment**

186 **Pathogen detection methods.**

187 **Infection detection.** COVID was diagnosed primarily by direct detection of SARS-CoV-2 RNA
188 by nucleic acid amplification tests with a real-time reverse-transcriptase-polymerase-chain-
189 reaction (RT-PCR) assay using nasal or pharyngeal swab specimens from the upper
190 respiratory tract. A health care professional collected a fluid sample by inserting a long
191 nasopharyngeal swab into a nostril and taking fluid from the back of a nose.

192 To diagnosis of the flu was used a RT-PCR test called the Flu SC2 Multiplex Assay. Sputum
193 DNA was extracted using Chemagic DNA kits (PerkinElmer, Turku, Finland) and PCR assays

194 were performed using Seeplex Pneumobacter ACE Detection kits (Seegene Inc., Seoul, South
195 Korea) according to the manufacturer protocol. (36)

196 Sputum specimens collection, samples transport, samples storage, diagnostic test
197 procedures environment, to tests results reporting, every step were strictly performed under
198 the standard guidelines. (37, 38)

199 All the tests were performed in two independent laboratories in Astana: BioLab laboratory and
200 OLIMP laboratory. Positive results were considered when both laboratories give equal results.

201 *Biochemical laboratory assessments* consisted of a complete blood cell count, white blood cells
202 (normal: $3.5-9.0 \times 10^9/L$), neutrophil-to-lymphocyte ratio (NLR) is calculated by dividing the
203 absolute count for neutrophils by the absolute count for lymphocytes (normal: 1-2), blood
204 chemical analysis, erythrocyte sedimentation rate, urea (normal: 2.1-7.7 mmol/L), creatinine
205 (normal: 53-115 $\mu\text{mol/L}$), glucose, cholesterol (normal: $<5.4 \text{ mmol/L}$), triglyceride (normal:
206 $<1.69 \text{ mmol/L}$), high-density lipoprotein (HDL) (normal: $>1.55 \text{ mmol/L}$), fibrinogen (normal: 2.0-
207 4.0 g/L), hepatic enzyme levels (ALT, norm $<36 \text{ U/L}$, AST, norm $<40 \text{ U/L}$), assessment of liver
208 and renal function, and measures of inflammation level, C-reactive protein (normal: ≤ 10.0
209 mg/L), and HbA1c (normal: $<5.7\%$; prediabetes: 5.7-6.5%, diabetes: $\geq 6.5\%$). All the data of
210 enrolled cases, including demographic information, clinical symptoms or signs, clinical
211 outcomes and laboratory findings on admission, were included in electronic medical records.

212 *Hormonal assays.* Fasting serum insulin was determined by immunoassay (Immunotech
213 Insulin Irma kit, Prague, Czech Republic). Hyperinsulinemia was considered $>12.5 \text{ nU/L}$. The
214 Homeostasis Model Assessment insulin resistance indexes (HOMA-IR) was used as surrogate
215 measure of insulin sensitivity as follows: $\text{HOMA-IR} = ((\text{fasting insulin in nU/L}) \times (\text{fasting glucose}$
216 $\text{in mmol/l})/22.5)$. Insulin resistance was considered if the index was >2 .

217 Diagnostic criteria for T2D were used the standards of American Diabetes Association in 2017.
218 (39) Hypertension was diagnosed by BP readings and from medical records. Physical activity

219 of patients was assessed by the number of steps measured by pedometers (Hoffmann-La
220 Roche Ltd, Basel, Switzerland).

221 The Nonalcoholic Steatohepatitis Clinical Research Network criteria was used to diagnose
222 NASH and from medical records. (40)

223 *Anthropometrical data.* Anthropometrical indicators included age (years), weight (kg), BMI
224 (kg/m²). Body composition parameters including fat mass (in % of total body weight and total
225 kg), fat free mass (kg), total body water (%), muscle mass (%), and bone mass (%) were
226 measured using a Tanita-SC330S Body Composition Analyzer (Tanita Corp., Tokyo, Japan).

227 *For ROS we measured* malondialdehyde (MDA, a marker of lipid peroxidation and degradation
228 product of oxidized fatty acids), superoxide dismutase (SOD) and catalase (antioxidant
229 enzymes), and advanced oxidation protein products (AOPP, markers of protein oxidation).
230 MDA (µmol/L) was measured using a thiobarbituric acid-reactive substance assay as described
231 by Yagi and modified by Ohkawa. (41)

232 Antioxidant enzymes were determined in erythrocyte hemolysates, in which hemoglobin
233 concentration was assayed using Drabkin's method. Superoxide dismutase was measured by
234 the method of Misra and Fridrovich. (42) Catalase was measured at $\lambda = 240$ nm at 25 °C;
235 catalase activity was expressed in U/g and one unit is considered as the amount of the enzyme
236 which decomposes 1 g of H₂O₂ in 1 min at 25 °C in pH =7.0. AOPP (µmol/L) were measured
237 by adding 40 µL of plasma to a 190 µL of mixture of 81% phosphate buffer solution, 10% glacial
238 acetic acid and 4% 1.16 mmol solution of KI, followed by 2 minutes absorbance at 340 nm on
239 a plate reader Multiscan Ascent using a spectrophotometric method. Chloramine-T solution
240 was used as calibrator. (43)

241 **Imaging.** Ultrasound images (GE Vivid 9 Ultrasound; GE Healthcare Worldwide USA,
242 Michigan) and chest CT (Siemens Somatom Sensation 32) were obtained. The key imaging
243 finding in the pneumonia were ground-glass opacity, distribution and extent of lung
244 abnormalities, including consolidation, cavitation and pleural effusion.

245 Chest CT assessment of the severity of lung changes. Each lung field was divided into three
246 equal zones. Each zone was assigned a score from 0–4 based on the percentage of lung
247 involved (0 = no abnormality, 1 = <25% of the zone involved, 2 = 25–50% involved, 3 = 51–
248 75% involved and 4 = >75% involved). The scores for all six zones of each CT examination
249 were summed to provide a cumulative chest radiographic score (range, 0–24). (44, 45)
250 Baseline and follow-up CT scans were reviewed in consensus by two radiologists with 10–25
251 years of experience. Laboratory tests, ultrasound and CT images, and an electrocardiogram
252 were performed, and sputum and blood samples were collected on the inclusion day.

253 **Intervention.** We used the “Analimentary detoxication” (ANADETO) weight loss method,
254 including calorie restriction to 50-100 kcal/day with fat-free vegetables (tomatoes and
255 cucumbers) with mandatory salt intake to 5-6 gr/day, hot water drinking 1000-1500 ml/day,
256 walking at least 2,000 steps/day after normalized body temperature, and sexual self-restraint.
257 The walking provided to promote of blood circulation and decrease in metabolic intoxication.
258 The weight loss method lasted 14 days. (46-48) Then the patients followed for 4-week a diet
259 where they ate one meal a day without any food restriction. A combination of in-person
260 conversations and telephone calls were conducted during whole 6-week study period.

261 **Ethics.** The Local Ethics Committee of the University Medical Center (phone: +71272-692586;
262 e-mails: mirgul.bayanova@umc.org.kz; <https://umc.org.kz/en/?ethics-commission>) approved
263 the study “The fast weight loss in patients with acute and chronic respiratory infections in
264 comorbidity with non-communicable diseases” (approval protocol number is #7 of 26.09.2019).

265 **Statistics** The two-side Student’s t-test and Odds ratios (ORs) with 95% Confidence intervals
266 (CIs) were used. The study data were tested against the normal distribution and are presented
267 in Tables as Mean±Standard Error of the Mean (M±SEM). *P*-value of <0.05 was set as
268 significant and <0.0001 was set as highly significant. Statistical analysis was performed using
269 SPSS ver.23.0 for Windows (SPSS: An IBM Company, Armonk, NY) and Microsoft Excel-2021.
270 All analyses were intention-to-treat.

271 **Trial Registration:** ClinicalTrials.gov NCT05635539. Registered 1 December 2022.

272 **3 RESULTS**

273 The symptoms of COVID and Influenza were the common typical such as fever in 62 patients
274 (100%), cough in 48 (77.4%), runny or stuffy nose in 51 (82.2%), fatigue in 49 (79%), chills in
275 30 (48.4%), sore throat in 14 (22.6%), headache in 22 (35.4%), body aches in 18 (29%). Loss
276 of taste or smell was in 21 patients (33.8%): 9 patients with COVID; 12 patients with Influenza.
277 This symptom did not differ between these diseases (95%; OR 0.96, CI 0.34-2.73, $P=0.46$).
278 Loss of appetite and smell irritability were in 51 patients (82.3%): 24 patients with COVID; 26
279 patients with Influenza (95%; OR 1.19, CI 0.81-1.77, $P=0.92$). Other clinical symptoms of the
280 diseases did not also differ from each other.

281 Baseline/ 7-day/ 14-day treatment and to 6-week follow-up results concerning anthropometrical
282 data, body composition, and metabolic data are shown in **Table 1**. Patients with overweight
283 lost from 8 to 11 kg (-12,4% from baseline), and it was higher than patients without overweight
284 (-9,14% from baseline; -9.7 ± 0.7 kg vs. -6.4 ± 0.6 kg, respectively; $P<0.001$) at 14-day of the
285 treatment. In patients with overweight BMI at 14-day was highly significantly decreased (-4.2
286 kg/m^2) than in patients without overweight (-2.2 kg/m^2) ($P<0.001$).

287 Weight loss in both groups was due to reduction of fat mass ($P<0.0001$). Percentages of total
288 body water and muscle mass tended to increase significantly in both groups at 7-day/14-day
289 of the treatment, and the percentage of bone mass increased significantly too (in patients with
290 overweight $P<0.0001$; in patients without overweight $P<0.05$). Lean body mass (fat free mass)
291 did not change significantly during weight loss in both groups, patients with and without
292 overweight ($P = 0.82-0.97$). These trends persisted at 6-week of follow-up.

293 Starting from 2-3 days of the treatment, in almost patients is increased a sputum production to
294 1.0-1.5 liters a day. A sputum production decreased by 7-9 days of the treatment.

295 Body temperature decreased starting from 3-4 days of treatment, and it is normalized to 6-9
296 days, and also was normal at 6-week follow-up (**Table 2**). Begin from 3-5 days of the treatment,

297 in most of the patients their urine became turbid, muddy and intensively darkly colored, which
298 persisted for several days. Urine microscopy showed organic and non-organic salts such as
299 oxalates, urates, phosphates, and carbonates of calcium and magnesium, and leukocyturia
300 (20-35 per in sight). Starting from 5-7 days of the treatment, the patients noticed a physical
301 relief, increase in physical/mental workability, and exercise tolerance. Infection detection at 14-
302 day of treatment was a negative in 26 patients with COVID of 27, and 34 patients with Influenza
303 of 35. Re-detection on the next two days showed a negative in both patients.

304 The weight loss treatment evoked significantly rising of serum urea and creatinine on 7-day of
305 treatment. We noticed normalization levels of serum urea and creatinine on 14-day. (**Table 2**)
306 During lipolysis on the weight loss treatment there was no protein lost because total serum
307 protein level significantly increased from baseline (62.41 ± 0.53 g/l) to 14-day treatment
308 (66.92 ± 0.65 g/l, $P < 0.0001$), and 6-week follow-up (71.43 ± 0.67 g/l, $P < 0.0001$). Hemoglobin
309 level also significantly increased from baseline (128.6 ± 0.71 g/l) to 14-day treatment
310 (131.7 ± 0.72 g/l, $P < 0.05$), and 6-week follow-up (136.9 ± 0.78 g/l, $P < 0.0001$). HDL significantly
311 increased from baseline (0.96 ± 0.03 mmol/L) to 14-day treatment (1.06 ± 0.03 mmol/L, $P = 0.02$),
312 and 6-week follow-up (1.68 ± 0.04 mmol/L, $P < 0.0001$). (**Table 2**)

313 White blood cells were gradually decreased on the 14 day. Relative lymphocyte count
314 increased that the NLR was significantly decreased ($P < 0.0001$). Total fibrinogen, C-reactive
315 protein, and Erythrocyte sedimentation rate were significantly decreased to normal at 14-day
316 of treatment ($P < 0.0001$) and 6-week follow-up ($P < 0.0001$). (**Table 2**)

317 The weight loss treatment led to a normal systolic/diastolic BP starting from 7-day of treatment,
318 and it were normalized at 14-day and 6-week follow-up (**Table 2**) reaching the levels
319 recommended by the American Heart Association (2014).

320 The positive changes in glucose metabolism in patients with T2D (n=26) were at 14-day of
321 treatment and also at 6-week follow-up. Fasting Glucose and Immunoassay Insulin, and
322 HOMA-IR index quickly decreased at 14-day of treatment. Insulin decreased 2.3-fold from

323 baseline at 14-day of treatment, whereas 3.5-fold from baseline at 6-week follow-up. HbA1c
324 decreased to the normal by 6-week (4.86 ± 0.08) by 31% ($P<0.05$).

325 Cholesterol and triglycerides are significantly increased by 17.2-6.4% and 68.8-62.7% from
326 baseline at 7 and 14 days of the treatment, respectively.

327 In patients with NASH (n=51) ALT and AST levels were significantly decreased from baseline
328 (134.3 ± 5.4 and 166.5 ± 5.5 U/L, respectively) at 7-day (by 102.6 ± 5.7 ($P<0.05$) and 126.3 ± 5.9
329 U/L ($P<0.0001$), respectively); and 14-day (by 78.4 ± 4.2 ($P<0.0001$) and 92.4 ± 4.9 U/L
330 ($P<0.0001$), respectively). On the 6-week follow-up ALT and AST levels returned to normal
331 ($P<0.0001$). (**Table 2**)

332 Platelets in patients with NASH (n=51) significantly increased from baseline 186.5 ± 4.6 , $\times 10^9/L$
333 at 14-day of treatment by 238.5 ± 5.8 , $\times 10^9/L$ ($P<0.0001$), and at 6-week follow-up by 278.3 ± 6.9 ,
334 $\times 10^9/L$ ($P<0.0001$).

335 *Abnormal chest imaging.* CT-scans were abnormal in 44 patients (70.97%) aged >40 years
336 old, including 8 patients with NASH, T2D and Hypertension; 6 patients with NASH and T2D;
337 12 patients with T2D and Hypertension; 18 patients with NASH and Hypertension.

338 CT findings included multiple small patchy shadows, centrilobular nodules and bronchial wall
339 thickening, interstitial inflammation, predominantly distributed in the peripheral of the lungs,
340 ground glass opacities and infiltrates in the lungs, bronchopneumonia patterns. The most
341 common finding was ground glass opacity (n=39; 88.6% including 25 patients with COVID),
342 not followed by consolidation. Pleural effusion and cavitation was not detected. Unilateral lung
343 involvement (n=36; 81.8%) was more common than bilateral involvement (n=6; 13.6%). The
344 right/ left lower zones (n=34; 77.3%) were more commonly affected than the right/ left middle
345 (n=9; 20.5%). Multifocal distribution was more common (n=24, 54.5%) than unifocal distribution
346 (n=19, 43.2%). Chest CT scans were non-specific for the ARDs.

347 The mean score of chest CT for the patients (n=44) was 13.12 ± 0.38 . A significant positive
348 changes was found on 14-day of treatment with the score 1.72 ± 0.12 ($P<0.0001$). There were

349 not found the lung abnormalities at 6-week follow-up (**Table 2**). By 14-day of treatment CT
350 scans showed that the scope of the lesions had been reduced, the density was gradually
351 decreased, the number of lesions decreased, and the ground glass opacities were absorbed.
352 There was no the 6-week risk of arterial thromboembolism and venous thromboembolism
353 among the patients with COVID or Influenza.

354 The oxidative products of lipids and proteins had a trend to normalize at 14-day treatment and
355 6-week follow-up, where MDA decreased by 31.7% at 14-day ($P<0.0001$) and by 48.4% at 6-
356 week from baseline ($P<0.0001$), AOPP decreased by 30.2% at 14-day ($P<0.0001$) and by
357 36.3% at 6-week from baseline ($P<0.0001$), and SOD increased by 66.9% ($P<0.0001$) and
358 Catalase by 76.6% at 14-day ($P<0.0001$), and by 92.4% and 85.8%, respectively, at 6-week
359 from baseline ($P<0.0001$) (**Table 2**).

360 As the clinical status of the patients was improving, the previous antidiabetic (patients with
361 T2D, n=26), antihypertensive (patients with hypertension, n=38), anti-inflammatory and
362 hepatoprotective (patients with NASH, n=51), and other symptomatic conventional medications
363 were adequately decreased starting from 2-5 days of ANADETO treatment. By days of 5 to 8
364 after the treatment start, the drugs were stopped completely. There were no recurrence of T2D,
365 hypertension, and NASH at 6-week follow-up.

366 **4. DISCUSSION**

367 Our data showed that the fast weight loss 'ANADETO' method (-12,4% fat loss in patients with
368 overweight, and -9,14% fat loss in patients without overweight) at 14-day treatment and at 6-
369 week follow-up had a clinical, laboratory and imaging effectiveness in patients with COVID and
370 Influenza in comorbidity with T2D, hypertension, and NASH.

371 The weight loss in patients with overweight goes faster than in patients without overweight.
372 This an interesting finding in the physiology of weight loss might be explained by different
373 structure of fat in people with and without overweight. (49) People who quickly weight gain can
374 accumulate a lightweight body fat, and people who slowly weight gain can accumulate a dense

375 body fat. Some people cannot weight gain that possibly related with genotype, different fat
376 structure, or metabolic equivalent when the same amount of fat can give different calorie. (50,
377 51)

378 The weight loss improved an immunity of the patients by significantly increased in lymphocyte
379 count and decreased in NLR. In fact, lymphopenia has also been associated with severe illness
380 and poorer survival in COVID-19. (52, 53) In clinical practice, it was observed that in some
381 non-survivors, the absolute value of lymphocytes decreases progressively while the white
382 blood cell count gradually increases over time, resulting in a “divergence” between the absolute
383 value of neutrophils and lymphocytes, that NLR, may be correlated with the progression and
384 prognosis of this newly emerged disease. (54)

385 Our clinical study confirmed that weight loss significantly reduces inflammation biomarkers.
386 (55, 56) Reducing inflammation through weight loss could be associated with reduced risk for
387 cardiovascular disease and other obesity-associated chronic diseases. (28, 57) The weight
388 loss has immunomodulatory effect, repealed insulin resistance, improved blood insulin,
389 increased blood hemoglobin, and improved blood pressure. (58, 59) The weight loss method
390 also decreased blood cholesterol/triglyceride, lipid/ protein oxidative products, and increased
391 anti-oxidative enzymes.

392 Increased serum urea and creatinine during 14-day weight loss can testify about endogen
393 intoxication related to active lipolysis. Adsorbed endogen organic toxins in adipocytes are
394 eliminated through blood system during lipolysis. (60, 61) Increase in lipids (cholesterol and
395 triglyceride) from baseline at 7 and 14 days of the treatment confirms the activity of lipolysis
396 during the weight loss treatment.

397 More sodium ions are eliminated through urine in patients with acute respiratory inflammation
398 in comorbidity with NCDs. (62, 63) Blood and urine sodium became normal on a weight loss
399 due to elimination of metabolic pollutants from the body.

400 Improvements of liver function we noticed by decrease in ALT and AST levels and increase in
401 blood platelets, and serum total protein. Weight loss improves liver health, cardiovascular risk,
402 and quality of life, therefore some authors offer it as feasible treatment option for patients
403 with NASH. (64, 65)

404 The study evidenced that chest CT in the patients with COVID and Influenza are highly variable
405 and nonspecific, that is considered with other authors. (66) Chest CT has been widely used
406 during the COVID pandemic, which has a high sensitivity, about 60-97%, but low specificity
407 (about 20-50%). (66, 67) Many radiology professional societies recommend against performing
408 chest CT as a primary technique for the diagnosis of COVID pneumonia. (68) In patients with
409 ARDs, CT findings should be interpreted in combination with a clinical context.

410 Overweight is a biological burden for the body, which consumes additional immunological,
411 antitoxic, trophic, excretion function. (69) The ANADETO method metabolizes 'old lipids' with
412 fat loss, decreases in inflammation, increases in immune response, improves of glucose and
413 lipid metabolism, and liver functions. The patients experienced side effects related to
414 symptoms of metabolic intoxication that is a common problem during weight loss. Adipose
415 tissue absorbs different persistent organic pollutants, (70) and plays an important role in storing
416 of different pollutants. (71)

417 The ability to accumulate adipose tissue is one of the most important adaptive mechanisms for
418 survival, but now we observe a steady increase in obesity and related diseases. (72, 73)

419 The fast weight loss method was a safe, well tolerated, and acceptable nutritional therapy
420 option for patients with acute respiratory inflammation diseases in comorbidity with T2D,
421 hypertension, and NASH. The optimal mix of caloric restriction, sodium intake, walking (at
422 normal body temperature), and sexual self-restraint behavior would be an effective treatment
423 method of ARDs (COVID and Influenza) in comorbidity with NCDs.

424 **5. CONCLUSIONS**

425 Thus, the fast weight loss ‘ANADETO’ cured clinical, laboratory, and instrumental data of
426 inflammation, improved glucose and lipids metabolism, normalized systolic/diastolic BPs and
427 NASH’s biochemical outcomes, decreased reactive oxygen species, and allowed drugs
428 reduction up to its complete withdrawal in patients with COVID and Influenza in comorbidity with
429 T2D, hypertension, and NASH. The weight loss occurred only due to a decrease in fat mass.

430 **Study limitation**

431 The study has several limitations. First, the study was short duration. Second, we did not study
432 T-cell and B-cell subpopulation. Third, the clinical trial had approximately 13.9% of the
433 assigned population dropped out prior to completion. Fourth, the study was non-randomized,
434 non-controlled trial. Fifth, published studies about positive role of weight loss in patients with
435 COVID and Influenza in comorbidity with Non-communicable diseases are limited in scope and
436 number. Further randomized controlled trials with longer-term follow-up are needed to confirm
437 and extend the results of the study.

438 **List of Abbreviations:**

ALT	– alanine aminotransferase
ANADETO	– ‘Analimentary detoxication’ weight loss method
AOPP	– advanced oxidation protein products
AST	– aspartate aminotransferase
BMI	– body mass index
BP	– blood pressure
CT	– Computed tomography
COVID	– SARS-CoV-2, a virus which causes the disease known as COVID-19
HbA1c	– glycosylated hemoglobin A1c
HDL	– high density lipoprotein
HOMA-IR	– Homeostasis Model Assessment for Insulin Resistance
M±SD	– Mean ± standard deviation
M±SEM	– Mean ± standard error of the mean
MDA	– malondialdehyde
NASH	– Nonalcoholic steatohepatitis

NCDs – non-communicable chronic diseases
ROS – reactive oxygen species
SOD – superoxide dismutase
T2D – type 2 diabetes mellitus

439 **DECLARATIONS**

440 **Ethics approval and consent to participate.** The Local Ethics Committee of the University
441 Medical Center (phone: +71272-692586; e-mails: mirgul.bayanova@umc.org.kz;
442 <https://umc.org.kz/en/?ethics-commission>) approved a study “The fast weight loss in patients
443 with acute and chronic respiratory infections in comorbidity with non-communicable diseases”
444 (approval protocol number is #7 of 26.09.2019).

445 **Consent for publication.** All authors of the manuscript affirm that they had access to the
446 study data and reviewed and approved the final version.

447 **Conflict of Interest Disclosures:** The authors declare that they have no any competing
448 interests (financial, professional, or personals) that are relevant to the manuscript. We have
449 read and understood the journal policy on declaration of interests and have no interests to
450 declare. Dukenbayeva Bibazhar, coauthor, she is a director of the Medical center
451 ‘ANADETO’, who participated in the study design, data interpretation, writing of discussion,
452 bibliography and paper review.

453 **Availability of data and materials.** First, the data is too large (> 2.8 GB). Secondly, we will
454 make our data available to any investigator/reviewer on their own request, so that the
455 personal privacy of our patients cannot be compromised.

456 **Funding sources:** This research was supported by Ministry of Education and Science of the
457 Republic of Kazakhstan (Grant for 2018-2021 years with trial registration AP05135241,
458 National Center for Scientific and Technical Information of the Republic of Kazakhstan. K.O.,
459 a PI of the project, is supported by the Ministry of health of the Republic of Kazakhstan,
460 2020-2021.

461 **Author contributions:**

462 *KO*: study design, collection of the clinical data, diagnosis and treatment of the patients,
463 bibliography review, statistical analysis, data interpretation, writing of the paper. *AD*: study
464 design, data collection, diagnosis and treatment of the patients, data interpretation,
465 bibliography and paper review. *AI*: study design, data collection, writing the Introduction and
466 Methods, data interpretation, paper review. *ZZ* and *MG*: preparation of the statistical data in
467 Excel, collection of the clinical data, bibliography and paper review, data interpretation,
468 statistical analysis, writing of the Methods and Discussion, paper review. *GB*: study design,
469 data collection, writing the results and discussion, and paper review. *AT*: writing of the
470 discussion, statistical analysis, paper review. *AN*: collection of the clinical data, preparation of
471 statistical data in Excel, patient diagnosis, bibliography search and review. *BD*: study design,
472 data collection and interpretation, writing the discussion, bibliography and paper review.
473 All authors read and approved the final manuscript.

474 **ACKNOWLEDGMENTS**

475 The authors thank the Republican Diagnostic Center at University Medical Center and
476 ANADETO medical center in recruiting patients and collecting data for the study, and
477 technical assistance.

478 **6. REFERENCES**

- 479 1. Federation. WO. Covid-19 and obesity: the 2021 atlas. March 2021. 227 p.
- 480 2. Li CX, Noreen S, Zhang LX, Saeed M, Wu PF, Ijaz M, et al. A critical analysis of SARS-CoV-2
481 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies.
482 *Biomedicine & Pharmacotherapy*. 2022;146.
- 483 3. Veronese N, Smith L, Di Gennaro F, Bruyere O, Yang L, Demurtas J, et al. Influenza Vaccination and
484 COVID-19 Outcomes in People Older than 50 Years: Data from the Observational Longitudinal SHARE Study.
485 *Vaccines*. 2022;10(6).
- 486 4. Bar-Yishay M, Yehoshua I, Bilitzky A, Press Y. Treatment outcomes of acute streptococcal tonsillitis
487 according to antibiotic treatment. A retrospective analysis of 242,366 cases treated in the community. *European*
488 *Journal of General Practice*. 2022;28(1):142-9.
- 489 5. Rahman MM, Bibi S, Rahaman MS, Rahman F, Islam F, Khan MS, et al. Natural therapeutics and
490 nutraceuticals for lung diseases: Traditional significance, phytochemistry, and pharmacology. *Chemical*
491 *Engineering Journal*. 2022;446.
- 492 6. Fang YY, Ni JC, Wang Y, Yu JH, Fu LL. Risk factors for hospital readmissions in pneumonia patients:
493 A systematic review and meta-analysis. *World Journal of Clinical Cases*. 2022;10(12):3787-800.

- 494 7. Sozzi FB, Gherbesi E, Faggiano A, Gnan E, Maruccio A, Schiavone M, et al. Viral Myocarditis:
495 Classification, Diagnosis, and Clinical Implications. *Frontiers in Cardiovascular Medicine*. 2022;9.
- 496 8. Shiels MS, Haque AT, de Gonzalez AB, Freedman ND. Leading Causes of Death in the US During the
497 COVID-19 Pandemic, March 2020 to October 2021. *Jama Internal Medicine*. 2022;182(8):883-+.
- 498 9. Moreland A, Gillezeau C, Eugene A, Alpert N, Taioli E. Ecologic study of influenza vaccination uptake
499 and COVID-19 death rate in New York City. *Bmc Public Health*. 2022;22(1).
- 500 10. Chetboun M, Raverdy V, Labreuche J, Simonnet A, Wallet F, Caussy C, et al. BMI and pneumonia
501 outcomes in critically ill covid-19 patients: An international multicenter study. *Obesity*. 2021;29(9):1477-86.
- 502 11. Bolla AM, Loretelli C, Montefusco L, Finzi G, Abdi R, Ben Nasr M, et al. Inflammation and vascular
503 dysfunction: The negative synergistic combination of diabetes and COVID-19. *Diabetes-Metabolism Research
504 and Reviews*.
- 505 12. Celik AI, Bezgin T, Baytugan NZ, Coskun R, Karaaslan MB, Cagdas M. Role of the coronary and non-
506 coronary cardiovascular findings on non-cardiac gated thoracic CT in predicting mortality in SARS-CoV-2
507 infection. *Clinical Imaging*. 2022;89:49-54.
- 508 13. Moctezuma-Velazquez P, Miranda-Zazueta G, Ortiz-Brizuela E, Alberto Garay-Mora J, Fernanda
509 Gonzalez-Lara M, Maria Tamez-Torres K, et al. NAFLD determined by Dallas Steatosis Index is associated
510 with poor outcomes in COVID-19 pneumonia: a cohort study. *Internal and Emergency Medicine*.
511 2022;17(5):1355-62.
- 512 14. NCD NCDRFC. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since
513 1980: a pooled analysis of 751 population-based studies with 4.4 million participants (vol 387, pg 1513, 2016).
514 *Lancet*. 2017;389(10068):E2-E.
- 515 15. NCD Risk Factor Collaboration (NCD-RisC)-Americas Working Group. Trends in cardiometabolic risk
516 factors in the Americas between 1980 and 2014: a pooled analysis of population-based surveys (vol 8, pg e123,
517 2020). *Lancet Global Health*. 2021;9(1):E23-E.
- 518 16. Al Noman A, Islam MS, Sana S, Mondal P, Meem RI, Rana S, et al. A review of the genome,
519 epidemiology, clinical features, prevention, and treatment scenario of COVID-19: Bangladesh aspects. *Egyptian
520 Journal of Bronchology*. 2021;15(1).
- 521 17. Rahman S, Montero MTV, Rowe K, Kirton R, Kunik F. Epidemiology, pathogenesis, clinical
522 presentations, diagnosis and treatment of COVID-19: a review of current evidence. *Expert Review of Clinical
523 Pharmacology*.
- 524 18. Park T, Hwang H, Moon S, Kang SG, Song S, Kim YH, et al. Vaccines against SARS-CoV-2 variants
525 and future pandemics. *Expert Review of Vaccines*.
- 526 19. Shah H, Khan MSH, Dhurandhar NV, Hegde V. The triumvirate: why hypertension, obesity, and
527 diabetes are risk factors for adverse effects in patients with COVID-19. *Acta Diabetologica*. 2021;58(7):831-43.
- 528 20. Ocker M. Challenges and opportunities in drug development for nonalcoholic steatohepatitis. *European
529 Journal of Pharmacology*. 2020;870.
- 530 21. Bouadma L, Mekontso-Dessap A, Burdet C, Merdji H, Poissy J, Dupuis C, et al. High-Dose
531 Dexamethasone and Oxygen Support Strategies in Intensive Care Unit Patients With Severe COVID-19 Acute
532 Hypoxemic Respiratory Failure The COVIDICUS Randomized Clinical Trial. *Jama Internal Medicine*.
- 533 22. Azh N, Barzkar F, Motamed-Gorji N, Pourvali-Talatappeh P, Moradi Y, Azad RV, et al. Nonsteroidal
534 anti-inflammatory drugs in acute viral respiratory tract infections: An updated systematic review. *Pharmacology
535 Research & Perspectives*. 2022;10(2).
- 536 23. Caci G, Albini A, Malerba M, Noonan DM, Pochetti P, Polosa R. COVID-19 and Obesity: Dangerous
537 Liaisons. *Journal of Clinical Medicine*. 2020;9(8).
- 538 24. Czernichow S, Bain SC, Capehorn M, Bogelund M, Madsen ME, Yssing C, et al. Costs of the COVID-
539 19 pandemic associated with obesity in Europe: A health-care cost model. *Clinical Obesity*. 2021;11(2).
- 540 25. Kompaniyets L, Goodman AB, Belay B, Freedman DS, Sucusky MS, Lange SJ, et al. Body Mass Index
541 and Risk for COVID-19-Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical
542 Ventilation, and Death-United States, March-December 2020. *Mmwr-Morbidity and Mortality Weekly Report*.
543 2021;70(10):355-61.
- 544 26. Oshakbayev K, Zhankalova Z, Gazaliyeva M, Mustafin K, Bedelbayeva G, Dukenbayeva B, et al.
545 Association between COVID-19 morbidity, mortality, and gross domestic product, overweight/ obesity, non-
546 communicable diseases, vaccination rate: A cross-sectional study. *Journal of infection and public health*.
547 2022;15(2):255-60.
- 548 27. Valerio A, Nisoli E, Rossi AP, Pellegrini M, Todesco T, El Ghoch M. Obesity and higher risk for severe
549 complications of COVID-19: What to do when the two pandemics meet. *Journal of Population Therapeutics and
550 Clinical Pharmacology*. 2020;27(2):E31-E6.

- 551 28. Heilbronn LK, de Jonge L, Frisard MI, DeLany JP, Larson-Meyer DE, Rood J, et al. Effect of 6-month
552 calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight
553 individuals: A randomized controlled trial (vol 295, pg 1539, 2006). *Jama-Journal of the American Medical*
554 *Association*. 2006;295(21):2482-.
- 555 29. Mendelsohn AR, Larrick JW. Dietary Restriction: Critical Co-Factors to Separate Health Span from
556 Life Span Benefits. *Rejuvenation Research*. 2012;15(5):523-9.
- 557 30. Mattison JA, Colman RJ, Beasley TM, Allison DB, Kemnitz JW, Roth GS, et al. Caloric restriction
558 improves health and survival of rhesus monkeys. *Nature Communications*. 2017;8.
- 559 31. Crupi AN, Haase J, Brandhorst S, Longo VD. Periodic and Intermittent Fasting in Diabetes and
560 Cardiovascular Disease. *Current Diabetes Reports*. 2020;20(12).
- 561 32. Krishnan A, Prichett L, Tao XT, Alqahtani SA, Hamilton JP, Mezey E, et al. Abnormal liver
562 chemistries as a predictor of COVID-19 severity and clinical outcomes in hospitalized patients. *World Journal*
563 *of Gastroenterology*. 2022;28(5):570-87.
- 564 33. Siegers JY, Novakovic B, Hulme KD, Marshall RJ, Bloxham CJ, Thomas WG, et al. A High-Fat Diet
565 Increases Influenza A Virus-Associated Cardiovascular Damage. *Journal of Infectious Diseases*.
566 2020;222(5):820-31.
- 567 34. Oshakbayev K, Dukenbayeva B, Togizbayeva G, Durmanova A, Gazaliyeva M, Sabir A, et al. Weight
568 loss technology for people with treated type 2 diabetes: a randomized controlled trial. *Nutrition & Metabolism*.
569 2017;14.
- 570 35. Oshakbayev K, Bimbetov B, Manekenova K, Bedelbayeva G, Mustafin K, Dukenbayeva B. Severe
571 nonalcoholic steatohepatitis and type 2 diabetes: liver histology after weight loss therapy in a randomized
572 clinical trial. *Current Medical Research and Opinion*. 2019;35(1):157-65.
- 573 36. Manual of Clinical Microbiology, 9th Ed. Manual of Clinical Microbiology, 9th Ed. 2007:1-2256.
- 574 37. Bruno LC. IQCP: Guideline and Helpful Tools for Implementation. *Laboratory Medicine*.
575 2016;47(4):E42-E6.
- 576 38. Jung CY, Choe YH, Lee SY, Kim WJ, Lees JD, Ra SW, et al. Use of serology and polymerase chain
577 reaction to detect atypical respiratory pathogens during acute exacerbation of chronic obstructive pulmonary
578 disease. *Korean Journal of Internal Medicine*. 2018;33(5):941-51.
- 579 39. Khunti K, Alsifri S, Aronson R, Berkovic MC, Enters-Weijnen C, Forsen T, et al. Impact of
580 hypoglycaemia on patient-reported outcomes from a global, 24-country study of 27,585 people with type 1 and
581 insulin-treated type 2 diabetes. *Diabetes Research and Clinical Practice*. 2017;130:121-9.
- 582 40. Brunt EM, Kleiner DE, Wilson LA, Sanyal AJ, Neuschwander-Tetri BA, Nonalcoholic S.
583 Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic
584 Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
585 *Hepatology*. 2019;70(2):522-31.
- 586 41. Ohishi N, Ohkawa H, Miike A, Tatano T, Yagi K. A NEW ASSAY-METHOD FOR LIPID
587 PEROXIDES USING A METHYLENE-BLUE DERIVATIVE. *Biochemistry International*. 1985;10(2):205-11.
- 588 42. Misra HP, Fridovich I. SUPEROXIDE-DISMUTASE - POSITIVE SPECTROPHOTOMETRIC
589 ASSAYS. *Analytical Biochemistry*. 1977;79(1-2):553-60.
- 590 43. Witko-Sarsat V, Friedlander M, Khoa TN, Capeillere-Blandin C, Nguyen AT, Canteloup S, et al.
591 Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic
592 renal failure. *Journal of Immunology*. 1998;161(5):2524-32.
- 593 44. Al Umairi RS, Al Salmi I, Al Kalbani J, Kamona A, Al Tai S, Al Kindi F, et al. COVID-2019
594 Pneumonia: Severity and distribution of lung changes observed on the initial chest X-ray as an indicator of final
595 outcomes. *Sultan Qaboos Univ Med J*. 2022;22(1):98-105.
- 596 45. Filchakova O, Dossym D, Ilyas A, Kuanysheva T, Abdizhamil A, Bukasov R. Review of COVID-19
597 testing and diagnostic methods. *Talanta*. 2022;244.
- 598 46. Oshakbayev KP, Alibek K, Ponomarev IO, Uderbayev NN, Dukenbayeva BA. Weight change therapy
599 as a potential treatment for end-stage ovarian carcinoma. *Am J Case Rep*. 2014;15:203-11.
- 600 47. Oshakbayev K, Dukenbayeva B, Otarbayev N, Togizbayeva G, Tabynbayev N, Gazaliyeva M, et al.
601 Weight loss therapy for clinical management of patients with some atherosclerotic diseases: a randomized
602 clinical trial. *Nutrition Journal*. 2015;14:9.
- 603 48. Oshakbayev KP, Seidaliyeva AP, Togizbayeva GI, Gazaliyeva MA, Durmanova AK, Idrisov AS, et al.
604 Clinical management with weight loss therapy in patients with Type 2 diabetes: a randomised clinical trial.
605 *Diabetic Medicine*. 2016;33:32-.
- 606 49. Taylor R, Holman RR. Normal weight individuals who develop Type 2 diabetes: the personal fat
607 threshold. *Clinical Science*. 2015;128(7):405-10.

- 608 50. Doo M, Won S, Kim Y. Association between the APOB rs1469513 polymorphism and obesity is
609 modified by dietary fat intake in Koreans. *Nutrition*. 2015;31(5):653-8.
- 610 51. Mahmoudi-Nezhad M, Farhangi MA, Kahroba H. Cocaine and amphetamine-regulated transcript
611 prepropeptide gene (CARTPT) polymorphism interacts with Diet Quality Index-International (DQI-I) and
612 Healthy Eating Index (HEI) to affect hypothalamic hormones and cardio-metabolic risk factors among obese
613 individuals. *Journal of Translational Medicine*. 2020;18(1).
- 614 52. Luo M, Liu J, Jiang WL, Yue S, Liu HG, Wei S. IL-6 and CD8(+) T cell counts combined are an early
615 predictor of in-hospital mortality of patients with COVID-19. *Jci Insight*. 2020;5(13).
- 616 53. Diao B, Wang CH, Tan YJ, Chen XW, Liu Y, Ning LF, et al. Reduction and Functional Exhaustion of T
617 Cells in Patients With Coronavirus Disease 2019 (COVID-19). *Frontiers in Immunology*. 2020;11.
- 618 54. Liu YP, Li GM, He J, Liu Y, Li M, Zhang R, et al. Combined use of the neutrophil-to-lymphocyte ratio
619 and CRP to predict 7-day disease severity in 84 hospitalized patients with COVID-19 pneumonia: a
620 retrospective cohort study. *Annals of Translational Medicine*. 2020;8(10).
- 621 55. Jung DY, Ko HJ, Lichtman EI, Lee E, Lawton E, Ong H, et al. Short-term weight loss attenuates local
622 tissue inflammation and improves insulin sensitivity without affecting adipose inflammation in obese mice.
623 *American Journal of Physiology-Endocrinology and Metabolism*. 2013;304(9):E964-E976.
- 624 56. Surendar J, Karunakaran I, Frohberger SJ, Koschel M, Hoerauf A, Hubner MP. Macrophages Mediate
625 Increased CD8 T Cell Inflammation During Weight Loss in Formerly Obese Mice. *Frontiers in Endocrinology*.
626 2020;11.
- 627 57. Le Roux C, Aminian A, Batterham R, Hesse D, Jensen C, McGowan B, et al. Weight Loss Outcomes
628 with Semaglutide 2.4 mg in Moderate or Severe Obesity in STEP 1 and 2. *Obesity*. 2021;29:46-.
- 629 58. Franz MJ, Boucher JL, Rutten-Ramos S, VanWormer JJ. Lifestyle Weight-Loss Intervention Outcomes
630 in Overweight and Obese Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis of
631 Randomized Clinical Trials. *Journal of the Academy of Nutrition and Dietetics*. 2015;115(9):1447-63.
- 632 59. Lorenzo PM, Sajoux I, Izquierdo AG, Gomez-Arbelaes D, Zulet MA, Abete I, et al. Immunomodulatory
633 effect of a very-low-calorie ketogenic diet compared with bariatric surgery and a low-calorie diet in patients
634 with excessive body weight. *Clinical Nutrition*. 2022;41(7):1566-77.
- 635 60. Konopelniuk VV, Goloborodko, II, Ishchuk TV, Synelnyk TB, Ostapchenko LI, Spivak MY, et al.
636 Efficacy of Fenugreek-based bionanocomposite on renal dysfunction and endogenous intoxication in high-
637 calorie diet-induced obesity rat model-comparative study. *Epma Journal*. 2017;8(4):377-90.
- 638 61. Oshakbayev KP, Dukenbayeva BA, Idrisov AS, Oshakbayev P. Endogen metabolic intoxication at
639 weight loss therapy in patients with metabolic syndrome. *Diabetic Medicine*. 2013;30:106-7.
- 640 62. Liamis G, Liberopoulos E, Barkas F, Elisaf M. Diabetes mellitus and electrolyte disorders. *World*
641 *Journal of Clinical Cases*. 2014;2(10):488-96.
- 642 63. Lee YM, Kim KS, Kim SA, Hong NS, Lee SJ, Lee DH. Prospective associations between persistent
643 organic pollutants and metabolic syndrome: A nested case-control study. *Science of the Total Environment*.
644 2014;496:219-25.
- 645 64. Scragg J, Avery L, Cassidy S, Taylor G, Haigh L, Boyle M, et al. Feasibility of a Very Low Calorie
646 Diet to Achieve a Sustainable 10% Weight Loss in Patients With Nonalcoholic Fatty Liver Disease. *Clinical and*
647 *Translational Gastroenterology*. 2020;11(9).
- 648 65. Schwenger KJP, Fischer SE, Jackson TD, Okrainec A, Allard JP. Non-alcoholic Fatty Liver Disease in
649 Morbidly Obese Individuals Undergoing Bariatric Surgery: Prevalence and Effect of the Pre-Bariatric Very Low
650 Calorie Diet. *Obesity Surgery*. 2018;28(4):1109-16.
- 651 66. Carlicchi E, Gemma P, Poerio A, Caminati A, Vanzulli A, Zompatori M. Chest-CT mimics of COVID-
652 19 pneumonia-a review article. *Emergency Radiology*. 2021;28(3):507-18.
- 653 67. Kim H, Hong H, Yoon SH. Diagnostic Performance of CT and Reverse Transcriptase Polymerase Chain
654 Reaction for Coronavirus Disease 2019: A Meta-Analysis. *Radiology*. 2020;296(3):E145-E55.
- 655 68. Ebrahimzadeh S, Islam N, Dawit H, Salameh JP, Kazi S, Fabiano N, et al. Thoracic imaging tests for
656 the diagnosis of COVID-19. *Cochrane Database of Systematic Reviews*. 2022(5).
- 657 69. Dirinck EL, Dirtu AC, Govindan M, Covaci A, Van Gaal LF, Jorens PG. Exposure to Persistent
658 Organic Pollutants: Relationship With Abnormal Glucose Metabolism and Visceral Adiposity. *Diabetes Care*.
659 2014;37(7):1951-8.
- 660 70. Pestana D, Faria G, Sa C, Fernandes VC, Teixeira D, Norberto S, et al. Persistent organic pollutant
661 levels in human visceral and subcutaneous adipose tissue in obese individuals-Depot differences and
662 dysmetabolism implications. *Environmental Research*. 2014;133:170-7.
- 663 71. Lee DH, Porta M, Jacobs DR, Vandenberg LN. Chlorinated Persistent Organic Pollutants, Obesity, and
664 Type 2 Diabetes. *Endocrine Reviews*. 2014;35(4):557-601.

- 665 72. Gribsholt SB, Cronin-Fenton D, Veres K, Thomsen RW, Ording AG, Richelsen B, et al. Hospital-
666 diagnosed overweight and obesity related to cancer risk: a 40-year Danish cohort study. *Journal of Internal*
667 *Medicine*. 2020;287(4):435-47.
- 668 73. Gielen M, Hageman GJ, Antoniou EE, Nordfjall K, Mangino M, Balasubramanyam M, et al. Body mass
669 index is negatively associated with telomere length: a collaborative cross-sectional meta-analysis of 87
670 observational studies. *American Journal of Clinical Nutrition*. 2018;108(3):453-75.

671

673 **Table 1** Anthropometrical data, body composition in patients (with/ without overweight) with
674 COVID and Influenza in comorbidity with the Non-communicable diseases before (baseline),
675 during treatment, and 6-week follow-up (M ± SEM)

Variables	Baseline	Treatment days		6-Week follow-up
		7 day	14 day	
Weight in patients with overweight (n=33) (kg)	83.15 ± 0.74	76.24 ± 0.79**	72.84 ± 0.72**	74.18 ± 0.89**
BMI (kg/m ²)	28.14 ± 0.39	26.07 ± 0.37*	24.91 ± 0.34**	25.37 ± 0.35**
Fat mass (%)	29.73 ± 0.45	22.90 ± 0.41**	19.54 ± 0.51**	21.94 ± 0.53**
Fat free mass (kg)	58.21 ± 0.43	58.09 ± 0.41	58.08 ± 0.41	58.23 ± 0.44
Total body water (%)	53.47 ± 0.43	57.32 ± 0.42**	62.13 ± 0.44**	62.33 ± 0.45**
Muscle mass (%)	65.45 ± 0.98	69.89 ± 1.02*	74.67 ± 1.06**	74.54 ± 1.09**
Bone mass (%)	3.61 ± 0.09	3.68 ± 0.09	3.83 ± 0.09	4.12 ± 0.09**
Weight in patients without overweight (n=29) (kg)	71.33 ± 0.81	67.98 ± 0.83*	64.81 ± 0.83**	66.12 ± 0.80**
BMI (kg/m ²)	23.37 ± 0.38	23.80 ± 0.37	21.23 ± 0.35*	22.15 ± 0.35*
Fat mass (%)	25.81 ± 0.43	23.43 ± 0.41*	19.81 ± 0.43**	20.93 ± 0.39**
Fat free mass (kg)	52.92 ± 0.52	52.05 ± 0.51	51.77 ± 0.48	52.28 ± 0.47
Total body water (%)	53.97 ± 0.46	55.22 ± 0.46	59.32 ± 0.48**	59.94 ± 0.48**
Muscle mass (%)	67.84 ± 0.97	68.76 ± 0.99	72.67 ± 0.98*	71.85 ± 0.98*
Bone mass (%)	3.78 ± 0.08	3.80 ± 0.09	3.97 ± 0.08	4.09 ± 0.10*

676
677 * *P*-value of < 0.05, and

678 ** *P* < 0.0001 were set as significant from baseline.

679 *Abbreviations:* BMI, body mass index; M, mean; SEM, standard error of the mean.

680

681

682 **Table 2** Body temperature, Blood pressures, Inflammation level, Glucose and Lipids
 683 metabolism, Lipid and protein oxidative products, and chest CT in patients with COVID and
 684 Influenza in comorbidity with the Non-communicable diseases at baseline, during treatment,
 685 and 6-week follow-up (M ± SEM)

Variables (n)	Baseline	Treatment days		6-Week follow-up
		7 day	14 day	
Body temperature, °C (62)	39.34 ± 0.08	37.86 ± 0.08**	36.7 ± 0.05**	36.5 ± 0.03**
Systolic BP in patients with hypertension, mmHg (38)	161.3 ± 1.31	116.2 ± 0.77**	118.3 ± 0.46**	120.8 ± 1.17**
Diastolic BP in patients with hypertension, mmHg (38)	101.6 ± 0.85	78.92 ± 0.67**	80.89 ± 0.66**	81.23 ± 0.79**
Total protein, g/l (62)	62.41 ± 0.63	--	66.92 ± 0.65**	71.43 ± 0.67**
Hemoglobin, g/L (62)	128.6 ± 0.71	--	131.7 ± 0.72*	136.9 ± 0.78**
White blood cells, ×10 ⁹ /L (62)	12.29 ± 0.17	11.83 ± 0.16	7.68 ± 0.12**	5.21 ± 0.09**
Neutrophil, ×10 ⁹ /L (62)	7.128 ± 0.012	6.389 ± 0.010**	3.610 ± 0.009**	2.501 ± 0.012**
Lymphocytes, ×10 ⁹ /L (62)	2.581 ± 0.008	3.256 ± 0.009**	2.918 ± 0.009**	1.824 ± 0.008**
Neutrophil-to-lymphocyte ratio (62)	2.762±0.009	1.962 ± 0.009**	1.237 ± 0.009**	1.371 ± 0.008**
Erythrocyte sedimentation rate, mm/Hour (62)	33.4 ± 0.56	--	13.76 ± 0.24**	7.59 ± 0.24**
Total Fibrinogen, g/L (62)	4.83 ± 0.07	5.25 ± 0.09*	3.81 ± 0.08**	2.92 ± 0.09**
C-reactive protein, mg/L (62)	34.86 ± 1.26	26.35 ± 1.37**	12.39 ± 0.79**	6.57 ± 0.74**
Glucose in patients with T2D, mmol/L (26)	12.86 ± 0.19	6.75 ± 0.11**	4.60 ± 0.09**	4.58 ± 0.10**
HbA1c, % (26)	7.03 ± 0.09	--	--	4.86 ± 0.08**
Immunoassay Insulin, nU/L (26)	22.38 ± 0.58	--	9.61 ± 0.22**	6.45 ± 0.17**
HOMA-IR index (26)	12.79 ± 0.35	--	1.96 ± 0.17**	1.31 ± 0.17**
Platelets, ×10 ⁹ /L (51)	186.5 ± 4.6	196.6 ± 4.7	238.5 ± 5.8**	278.3 ± 6.9**

ALT, U/L (51)	134.3 ± 5.4	102.6 ± 5.7*	78.4 ± 4.2**	27.5 ± 1.8**
AST, U/L (51)	166.5 ± 5.5	126.3 ± 5.9**	92.4 ± 4.9**	29.3 ± 1.8**
Urea, mmol/L (62)	5.17 ± 0.07	7.54 ± 0.07**	5.62 ± 0.06**	4.14 ± 0.07**
Creatinine, µmol/L (62)	75.58 ± 1.27	109.73 ± 1.59**	62.86 ± 1.07**	58.45 ± 0.94**
Cholesterol, mmol/L (62)	5.82 ± 0.07	6.83 ± 0.08**	6.19 ± 0.09*	4.74 ± 0.07**
Triglyceride, mmol/L (62)	2.52 ± 0.07	5.94 ± 0.09**	5.73 ± 0.08**	1.11 ± 0.05**
HDL, mmol/L (62)	0.96 ± 0.03	1.02 ± 0.03	1.06 ± 0.03*	1.68 ± 0.04**
MDA, µmol/L (62)	60.74 ± 1.84	--	41.51 ± 0.87**	31.37 ± 0.86**
AOPP, µmol/L (62)	295.6 ± 9.2	--	206.3 ± 11.1**	188.3 ± 7.4**
SOD, U/mg (62)	34.58 ± 1.07	--	57.72 ± 1.06**	66.53 ± 0.98**
Catalase, U/g (62)	26.52 ± 0.67	--	46.83 ± 0.65**	49.29 ± 0.71**
Chest CT scan, score (44)	13.12 ± 0.38	--	1.72 ± 0.12**	0.0 ± 0.0

686

687 * *P*-value of < 0.05, and

688 ** *P* < 0.0001 were set as significant from baseline.

689 *Abbreviations:* AOPP, Advanced oxidation protein products; BP, blood pressure; CT, Computed
 690 tomography; HDL, high density lipoprotein; HOMA-IR, Homeostasis Model Assessment for Insulin
 691 Resistance; M, mean; MDA, Malondialdehyde; SOD, Superoxide dismutase; SEM, standard error of
 692 the mean; T2D, type 2 diabetes.

693

Figure 1. Participant Flow Diagram

